Vetoquinol SA AI Price Prediction

With EPS of €5.10 and a PE ratio of 16.24, Vetoquinol SA appears reasonably valued relative to typical mid-cap pharma/animal health peers, suggesting neither clear undervaluation nor overvaluation based solely on earnings. The figures imply the company is solidly profitable, but without explicit revenue and margin trend data, it is difficult to argue for a strong re‑rating case purely on fundamentals.

• EPS of €5.10 and a share price of €82.80 yield a PE of 16.24, pointing to a moderate valuation that reflects established profitability but not high-growth expectations.
• The earnings multiple suggests the market prices Vetoquinol as a stable, mature business rather than a high‑beta growth story, which tempers upside but also limits downside if earnings are steady.
• Lack of explicit revenue, gross margin, and net income trend data keeps the view on fundamentals balanced; there is no strong evidence of accelerating or deteriorating profitability in the provided information.

The stock has risen 16.6% over the last month and trades above its 200‑day moving average, indicating a positive medium‑term trend. However, an RSI of 34.67 is close to oversold territory, suggesting recent selling pressure or consolidation after the run‑up, which tempers a strongly bullish technical view.

• Current price of €82.80 versus a 200‑day moving average of €75.67 indicates the longer‑term trend remains upward and the stock is trading at a premium to its medium‑term average.
• A 16.6% gain in the last month signals strong recent momentum, but such a rapid move can invite profit‑taking and short‑term volatility.
• RSI at 34.67 is below the neutral 50 level and approaching oversold territory (30), implying that, despite the recent monthly gain, near‑term sentiment has cooled and the stock may be in a consolidation or pullback phase rather than in a clear breakout.

Alternative data for Vetoquinol SA is mostly flat, with web traffic and app downloads showing 0.0% month‑over‑month growth, suggesting stable but not accelerating digital engagement. The notable positive is a 36.4% increase in job openings, which can indicate investment in growth or new initiatives, while social media audiences are small and largely stagnant, limiting their positive signal strength.

• Web traffic at an estimated 11,803 visitors per month and app downloads at 8,000 per day both show 0.0% month‑over‑month growth, pointing to stable but non‑accelerating customer or stakeholder engagement online.
• Job openings rising to 15, up 36.4% month over month, may signal expansion, new projects, or geographic/product growth, which is a modestly positive forward‑looking indicator if sustained.
• Social media presence is limited (e.g., 141 followers on Twitter/X, 838 on Instagram, 8,309 on Facebook, 594 on YouTube, and 59,210 on LinkedIn) with minimal growth over 90 days, suggesting that brand visibility and digital marketing momentum are not currently major upside catalysts.

Overall, Vetoquinol SA presents as a reasonably valued, profitable company with a positive medium‑term price trend but mixed short‑term technicals and largely flat alternative data signals. The combination of a moderate PE, solid EPS, price above the 200‑day moving average, and limited evidence of accelerating demand or engagement supports a neutral outlook rather than a distinctly bullish or bearish stance.

• Fundamentals and valuation (EPS of €5.10 and PE of 16.24) appear balanced, suggesting neither clear mispricing nor strong earnings‑driven upside without new catalysts.
• Technicals show the stock above its 200‑day moving average and up strongly over the last month, but an RSI near oversold and flat alternative data (web traffic, app downloads, social followers) argue for a cautious, neutral view pending clearer signs of growth acceleration.